US 12168036
Methods for treating angiogenic eye disorders with high doses of VEGF receptor fusion proteins
granted A61KA61K38/179A61K39/39591
Quick answer
US patent 12168036 (Methods for treating angiogenic eye disorders with high doses of VEGF receptor fusion proteins) held by REGENERON PHARMACEUTICALS, INC. expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 38
- CPC classes
- A61K, A61K38/179, A61K39/39591, A61K47/12, A61K47/183